Embecta (NASDAQ:EMBC) and Selectis Health (OTCMKTS:GBCS) Financial Review

Selectis Health (OTCMKTS:GBCS) and Embecta (NASDAQ:EMBC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and target prices for Selectis Health and Embecta, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Selectis Health	0	0	0	0	0.00
Embecta	0	3	1	0	2.25

Embecta has a consensus price target of $18.50, indicating a potential upside of 115.87%. Given Embecta’s stronger consensus rating and higher probable upside, analysts plainly believe Embecta is more favorable than Selectis Health.

Valuation & Earnings

This table compares Selectis Health and Embecta”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Selectis Health	$39.49 million	0.33	-$2.42 million	($0.27)	-15.56
Embecta	$1.08 billion	0.47	$95.40 million	$2.37	3.62

Embecta has higher revenue and earnings than Selectis Health. Selectis Health is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

93.8% of Embecta shares are owned by institutional investors. 15.2% of Selectis Health shares are owned by company insiders. Comparatively, 1.3% of Embecta shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Dividends

Selectis Health pays an annual dividend of $0.04 per share and has a dividend yield of 1.0%. Embecta pays an annual dividend of $0.60 per share and has a dividend yield of 7.0%. Selectis Health pays out -14.8% of its earnings in the form of a dividend. Embecta pays out 25.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Volatility and Risk

Selectis Health has a beta of -1.03, indicating that its share price is 203% less volatile than the S&P 500. Comparatively, Embecta has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500.

Profitability

This table compares Selectis Health and Embecta’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Selectis Health	-1.87%	N/A	-2.34%
Embecta	12.92%	-26.66%	16.06%

Summary

Embecta beats Selectis Health on 13 of the 16 factors compared between the two stocks.

About Selectis Health

Selectis Health owns and/or operates healthcare facilities in Arkansas, Georgia, Ohio, and Oklahoma, providing a wide array of living services, speech, occupational, physical therapies, social services, and other rehabilitation and healthcare services. Selectis focuses on building strategic relationships with local communities in which its partnership can improve the quality of care for facility residents. With its focused growth strategy, Selectis intends to deepen its American Southcentral and Southeastern market presence to better serve the aging population along a full continuum of care.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.